188 related articles for article (PubMed ID: 37299013)
1. Design, Synthesis, and Anti-Cervical Cancer and Reversal of Tumor Multidrug Resistance Activity of Novel Nitrogen-Containing Heterocyclic Chalcone Derivatives.
Yang Z; Liu ZY; Ablise M; Maimaiti A; Mutalipu Z; Alimujiang Y; Aihaiti A
Molecules; 2023 Jun; 28(11):. PubMed ID: 37299013
[TBL] [Abstract][Full Text] [Related]
2. Design and synthesis of novel imidazole-chalcone derivatives as microtubule protein polymerization inhibitors to treat cervical cancer and reverse cisplatin resistance.
Liu Z; Yang Z; Ablise M
Bioorg Chem; 2024 Jun; 147():107310. PubMed ID: 38583249
[TBL] [Abstract][Full Text] [Related]
3. Design and Synthesis of Novel α-Methylchalcone Derivatives, Anti-Cervical Cancer Activity, and Reversal of Drug Resistance in HeLa/DDP Cells.
Yang Z; Liu Z; Ablise M; Maimaiti A; Aihaiti A; Alimujiang Y
Molecules; 2023 Nov; 28(23):. PubMed ID: 38067428
[TBL] [Abstract][Full Text] [Related]
4. Design, Synthesis and Bioactivity Evaluation of Novel Chalcone Derivatives Possessing Tryptophan Moiety with Dual Activities of Anti-Cancer and Partially Restoring the Proliferation of Normal Kidney Cells Pre-Treated with Cisplatin.
He M; Yu M; Li C; Meng X; Su J; Zhu Y; Yao R
Anticancer Agents Med Chem; 2022; 22(10):1945-1961. PubMed ID: 34674626
[TBL] [Abstract][Full Text] [Related]
5. TMEM45A Affects Proliferation, Apoptosis, Epithelial-Mesenchymal Transition, Migration, Invasion and Cisplatin Resistance of HPV-Positive Cervical Cancer Cell Lines.
Liu Y; Liu L; Mou ZX
Biochem Genet; 2022 Feb; 60(1):173-190. PubMed ID: 34143331
[TBL] [Abstract][Full Text] [Related]
6. Molecular Docking Study, Cytotoxicity, Cell Cycle Arrest and Apoptotic Induction of Novel Chalcones Incorporating Thiadiazolyl Isoquinoline in Cervical Cancer.
Tantawy MA; Sroor FM; Mohamed MF; El-Naggar ME; Saleh FM; Hassaneen HM; Abdelhamid IA
Anticancer Agents Med Chem; 2020; 20(1):70-83. PubMed ID: 31696811
[TBL] [Abstract][Full Text] [Related]
7. Design, Synthesis, and In vitro Anti-cervical Cancer Activity of a Novel MDM2-p53 Inhibitor Based on a Chalcone Scaffold.
Alimujiang Y; Maimaiti A; Ablise M; Yang Z; Liu Z; Wang Y; Mutalipu Z; Yan T
Anticancer Agents Med Chem; 2024 Jan; ():. PubMed ID: 38204258
[TBL] [Abstract][Full Text] [Related]
8. Design and development of novel 1,2,3-triazole chalcone derivatives as potential anti-osteosarcoma agents
Su Q; Xu B; Tian Z; Gong Z
Acta Pharm; 2022 Sep; 72(3):389-402. PubMed ID: 36651540
[TBL] [Abstract][Full Text] [Related]
9. Design, synthesis, and validation of novel nitrogen-based chalcone analogs against triple negative breast cancer.
Elkhalifa D; Siddique AB; Qusa M; Cyprian FS; El Sayed K; Alali F; Al Moustafa AE; Khalil A
Eur J Med Chem; 2020 Feb; 187():111954. PubMed ID: 31838326
[TBL] [Abstract][Full Text] [Related]
10. Biological evaluation of polycyclic chalcone based acrylamides in human MCF-7 and HeLa cancer cell lines.
Gunasekaran V; Yuvakkumar R; Ganesan R; Palapetta SC; Gurusamy H
Environ Res; 2023 Apr; 222():115395. PubMed ID: 36731601
[TBL] [Abstract][Full Text] [Related]
11. Inhibiting the cytoplasmic location of HMGB1 reverses cisplatin resistance in human cervical cancer cells.
Xia J; Yu X; Song X; Li G; Mao X; Zhang Y
Mol Med Rep; 2017 Jan; 15(1):488-494. PubMed ID: 27959427
[TBL] [Abstract][Full Text] [Related]
12. Discovery of pyrimidine-bridged CA-4 CBSIs for the treatment of cervical cancer in combination with cisplatin with significantly reduced nephrotoxicity.
Huo Z; Liu K; Zhang X; Liang Y; Sun X
Eur J Med Chem; 2022 May; 235():114271. PubMed ID: 35339837
[TBL] [Abstract][Full Text] [Related]
13. Design, synthesis and bioevaluation of novel prenylated chalcones derivatives as potential antitumor agents.
Yu J; Wang X; Cheng S; Zeng X; Wan X; Wei S; Xu B; Luo H; Meng X
Eur J Pharm Sci; 2024 Jan; 192():106660. PubMed ID: 38052256
[TBL] [Abstract][Full Text] [Related]
14. Antiproliferative Evaluation of Some 2-[2-(2-Phenylethenyl)-cyclopent-3-en-1-yl]-1,3-benzothiazoles: DFT and Molecular Docking Study.
Ceylan M; Erkan S; Yaglioglu AS; Akdogan Uremis N; Koç E
Chem Biodivers; 2020 Apr; 17(4):e1900675. PubMed ID: 32141675
[TBL] [Abstract][Full Text] [Related]
15. Cyanidin-3-O-glucoside and cisplatin inhibit proliferation and downregulate the PI3K/AKT/mTOR pathway in cervical cancer cells.
Li X; Zhao J; Yan T; Mu J; Lin Y; Chen J; Deng H; Meng X
J Food Sci; 2021 Jun; 86(6):2700-2712. PubMed ID: 33908630
[TBL] [Abstract][Full Text] [Related]
16. Design and Synthesis of Novel Chalcone Derivatives: Anti-Breast Cancer Activity Evaluation and Docking Study.
Lai W; Chen J; Gao X; Jin X; Chen G; Ye L
Int J Mol Sci; 2023 Oct; 24(21):. PubMed ID: 37958533
[TBL] [Abstract][Full Text] [Related]
17. SPP1 inhibition improves the cisplatin chemo-sensitivity of cervical cancer cell lines.
Chen X; Xiong D; Ye L; Yang H; Mei S; Wu J; Chen S; Mi R
Cancer Chemother Pharmacol; 2019 Apr; 83(4):603-613. PubMed ID: 30627777
[TBL] [Abstract][Full Text] [Related]
18. Identification of novel sulfathiazole-triazolo-chalcone hybrids as VEGFR-2/EGFR dual inhibitors with antiangiogenic activity and apoptotic induction.
Zeidan MA; Othman DIA; Goda FE; Mostafa AS
Arch Pharm (Weinheim); 2024 Mar; 357(3):e2300320. PubMed ID: 38117940
[TBL] [Abstract][Full Text] [Related]
19. Novel piperazine-chalcone hybrids and related pyrazoline analogues targeting VEGFR-2 kinase; design, synthesis, molecular docking studies, and anticancer evaluation.
Ahmed MF; Santali EY; El-Haggar R
J Enzyme Inhib Med Chem; 2021 Dec; 36(1):307-318. PubMed ID: 33349069
[TBL] [Abstract][Full Text] [Related]
20. Synthesis and biological evaluation of novel ligustrazine-chalcone derivatives as potential anti-triple negative breast cancer agents.
Luo Y; Wu W; Zha D; Zhou W; Wang C; Huang J; Chen S; Yu L; Li Y; Huang Q; Zhang J; Zhang C
Bioorg Med Chem Lett; 2021 Sep; 47():128230. PubMed ID: 34186178
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
